88 related articles for article (PubMed ID: 17294577)
21. Can thiazolidinediones delay disease progression in type 2 diabetes?
Leiter LA
Curr Med Res Opin; 2006 Jun; 22(6):1193-201. PubMed ID: 16846552
[TBL] [Abstract][Full Text] [Related]
22. Effect of short-term rosiglitazone therapy in peritoneal dialysis patients.
van Hooland S; Boey O; Van der Niepen P; Van den Branden C; Verbeelen D
Perit Dial Int; 2009; 29(1):108-11. PubMed ID: 19164260
[No Abstract] [Full Text] [Related]
23. [Clinical utilization of combined rosiglitazone and glimepiride in the treatment of type 2 diabetes mellitus].
Fehér J; Lengyel G
Orv Hetil; 2007 Dec; 148(49):2331-5. PubMed ID: 18048112
[TBL] [Abstract][Full Text] [Related]
24. [The pharmacological prevention and treatment of diabetes mellitus; significance of 2 recent, large studies for the use of rosiglitazone].
Veneman TF
Ned Tijdschr Geneeskd; 2007 Mar; 151(9):514-6. PubMed ID: 17373390
[TBL] [Abstract][Full Text] [Related]
25. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study.
Zinman B; Harris SB; Neuman J; Gerstein HC; Retnakaran RR; Raboud J; Qi Y; Hanley AJ
Lancet; 2010 Jul; 376(9735):103-11. PubMed ID: 20605202
[TBL] [Abstract][Full Text] [Related]
26. DREAM and ADOPT: rosiglitazone does what it says on the packet.
Bilous R
Diabet Med; 2007 Feb; 24(2):107-9. PubMed ID: 17257270
[No Abstract] [Full Text] [Related]
27. Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance.
Durbin RJ
Diabetes Obes Metab; 2004 Jul; 6(4):280-5. PubMed ID: 15171752
[TBL] [Abstract][Full Text] [Related]
28. Pioglitazone for diabetes prevention in impaired glucose tolerance.
DeFronzo RA; Tripathy D; Schwenke DC; Banerji M; Bray GA; Buchanan TA; Clement SC; Henry RR; Hodis HN; Kitabchi AE; Mack WJ; Mudaliar S; Ratner RE; Williams K; Stentz FB; Musi N; Reaven PD;
N Engl J Med; 2011 Mar; 364(12):1104-15. PubMed ID: 21428766
[TBL] [Abstract][Full Text] [Related]
29. Effects of rosiglitazone and aspirin on experimental model of induced type 2 diabetes in rats: focus on insulin resistance and inflammatory markers.
Abdin AA; Baalash AA; Hamooda HE
J Diabetes Complications; 2010; 24(3):168-78. PubMed ID: 19328014
[TBL] [Abstract][Full Text] [Related]
30. [Efficacy of complex therapy with metformin and ramipril combination for patients with metabolic syndrome].
Kaĭdashev IP; Savchenko LH; Kaĭdasheva EI; Kutsenko NL; Kutsenko LO; Solokhina IL; Mamontova TV
Lik Sprava; 2010; (7-8):77-84. PubMed ID: 21714292
[TBL] [Abstract][Full Text] [Related]
31. Role of renin-angiotensin system blockade in patients with diabetes mellitus.
Braga MF; Leiter LA
Am J Cardiol; 2009 Sep; 104(6):835-9. PubMed ID: 19733720
[TBL] [Abstract][Full Text] [Related]
32. [Glucose-independent impact of the glitazones on the cardiovascular outcome].
Hanefeld M
MMW Fortschr Med; 2005 Jan; 147(1-2):37-9. PubMed ID: 15704569
[TBL] [Abstract][Full Text] [Related]
33. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
34. Targeting insulin resistance and beta-cell dysfunction: the role of thiazolidinediones.
Del Prato S; Marchetti P
Diabetes Technol Ther; 2004 Oct; 6(5):719-31. PubMed ID: 15628822
[TBL] [Abstract][Full Text] [Related]
35. Synergistic improvement in insulin resistance with a combination of fenofibrate and rosiglitazone in obese type 2 diabetic mice.
Choi WS; Lee JJ; Kim Y; Kim IS; Zhang WY; Myung CS
Arch Pharm Res; 2011 Apr; 34(4):615-24. PubMed ID: 21544727
[TBL] [Abstract][Full Text] [Related]
36. Preventing type 2 diabetes using combination therapy: design and methods of the CAnadian Normoglycaemia Outcomes Evaluation (CANOE) trial.
Zinman B; Harris SB; Gerstein HC; Young TK; Raboud JM; Neuman J; Hanley AJ
Diabetes Obes Metab; 2006 Sep; 8(5):531-7. PubMed ID: 16918588
[TBL] [Abstract][Full Text] [Related]
37. [41th Congress of EASD (European Association for The Study of Diabetes) 10 to 15 September 2005, Athens, Greece].
Simorre B
Rev Med Interne; 2006 Apr; 27(4):356-7. PubMed ID: 16703668
[No Abstract] [Full Text] [Related]
38. Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study.
Bailey SD; Xie C; Do R; Montpetit A; Diaz R; Mohan V; Keavney B; Yusuf S; Gerstein HC; Engert JC; Anand S;
Diabetes Care; 2010 Oct; 33(10):2250-3. PubMed ID: 20628086
[TBL] [Abstract][Full Text] [Related]
39. Withdrawal of pioglitazone in patients with type 2 diabetes mellitus.
Iwase M; Asano T; Sasaki N; Yoshizumi H; Hiramatsu S; Sakai Y; Ogo A; Iida M
J Clin Pharm Ther; 2010 Aug; 35(4):401-8. PubMed ID: 20831543
[TBL] [Abstract][Full Text] [Related]
40. Selective imidazoline agonist moxonidine plus the ACE inhibitor ramipril in hypertensive patients with impaired insulin sensitivity: partners in a successful MARRIAGE?
Rayner B
Curr Med Res Opin; 2004 Mar; 20(3):359-67. PubMed ID: 15025845
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
